shareholdersunite.com

Opportunities in smallcaps

shareholdersunite.com header image 4

IsoRay Is Set For Further Growth

February 23rd, 2020 · Comments Off on IsoRay Is Set For Further Growth

IsoRay’s proprietary Cesium-131 based therapies have cost, effectiveness and side effect advantages, which are leading to increased application. It is still in the early innings of capturing an increasing market. Besides brachytherapy for prostate cancer, which is the main usage today, the seeds can be used against other cancers, and the company has no international […]

[Read more →]

Tags: ISR

IsoRay Likely Has Further To Rise

December 11th, 2019 · Comments Off on IsoRay Likely Has Further To Rise

The company’s Cesium-131 based cancer treatments are effective, cheap and produce less side effects than other radiation. The company’s market cap is small in relation to its first big target market, prostate cancer. But there is another big market in treating brain cancer and a number of smaller additional applications. The company is displaying impressive […]

[Read more →]

Tags: ISR

IsoRay Has Exciting Prospects

July 15th, 2018 · Comments Off on IsoRay Has Exciting Prospects

The shares of the cancer therapy producer were buffeted by FDA approval and dilution. Their Cesium-131 based brachytherapy solutions show a lot of promise, not only in combating prostate cancer where they get most of their revenues. The company has a chance to scale up with the FDA approval, but they will have to speed […]

[Read more →]

Tags: ISR